AstraZeneca PLC
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Net cash inflow from operating activities by Year
Net cash inflow from operating activities ($M) ($M)
AstraZeneca Net cash inflow from operating activities: $14,575M in FY2025, up 22.9% from a year earlier. That is the highest of the 11 years on record here.
Where the FY2025 figure comes from
“|| Net cash inflow from operating activities | 14,575 | 11,861 | 2,714”
Source: Form 6-K FY2025Q4 Earnings Release ↗
Reported in Form 6-K Quarterly (period-split Q1–Q4) & Form 20-F Cash Flow Statement.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Net cash inflow from operating activities ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 14,575 | +22.9% | Form 6-K FY2025Q4 Earnings Release ↗ |
| FY2024 | Dec 31, 2024 | 11,861 | +14.7% | Form 6-K FY2024Q4 Earnings Release ↗ |
| FY2023 | Dec 31, 2023 | 10,345 | +5.5% | Form 6-K FY2023Q4 Earnings Release ↗ |
| FY2022 | Dec 31, 2022 | 9,808 | +64.5% | Form 6-K FY2022Q4 Earnings Release ↗ |
| FY2021 | Dec 31, 2021 | 5,963 | +24.3% | Form 6-K FY2021Q4 Earnings Release ↗ |
| FY2020 | Dec 31, 2020 | 4,799 | +61.6% | Form 6-K FY2020Q4 Earnings Release ↗ |
| FY2019 | Dec 31, 2019 | 2,969 | +13.4% | Form 20-F (filed 2020-03-03) ↗ |
| FY2018 | Dec 31, 2018 | 2,618 | -26.8% | Form 20-F (filed 2019-03-05) ↗ |
| FY2017 | Dec 31, 2017 | 3,578 | -13.7% | Form 20-F (filed 2018-03-06) ↗ |
| FY2016 | Dec 31, 2016 | 4,145 | +24.7% | Form 20-F (filed 2018-03-06) ↗ |
| FY2015 | Dec 31, 2015 | 3,324 | – | Form 20-F (filed 2018-03-06) ↗ |
Breakdown
What makes up net cash inflow from operating activities
- Net cash inflow before financing activities ($M)7,767 · FY2025
- Movement in working capital & short-term provisions ($M)-1,137 · FY2025
- Income tax paid ($M)-2,845 · FY2025
- Interest paid ($M)-1,316 · FY2025
- Purchase of property, plant and equipment (Capex) ($M)-2,810 · FY2025
- Purchase of intangible assets ($M)-3,095 · FY2025
- Dividends paid to shareholders ($M)-4,971 · FY2025
Cite this data
StockData. (2026). AstraZeneca Net cash inflow from operating activities ($M), annual FY2015–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/cf-operating
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.